GlassScriptPhysician profile
Nicole B Danner
NPI 1245202050
$92,933.50
in general payments reported to CMS, 2019-2025
36 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $21K · 2022: $15K · 2023: $10K · 2024: $9,289 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $2,673 · Education: $355 · Travel and Lodging: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,581.25 |
| Food and Beverage | $2,673.43 |
| Education | $354.67 |
| Travel and Lodging | $166.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57,146.79 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $32,752.30 | 2019-2021 | |
| Harmony Biosciences LLC | $418.85 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $319.00 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $249.17 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $191.48 | 2019-2020 | |
| Lundbeck LLC | $163.86 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $155.09 | 2019-2025 | Austedo Xr |
| Inspire Medical Systems, INC. | $137.09 | 2023-2024 | Inspire |
| Eisai INC. | $134.49 | 2019 | |
| Argenx US, INC. | $133.82 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $128.79 | 2022-2025 | Zeposia |
| Emd Serono, INC. | $124.90 | 2019 | |
| Silk Road Medical, INC. | $122.93 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Amgen INC. | $98.45 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $83.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $82.73 | 2020-2025 | Ultomiris |
| Genentech USA, INC. | $75.66 | 2019-2024 | Ocrevus |
| Merz North America, INC. | $51.38 | 2019 | |
| Genzyme Corporation | $44.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.83 | 2019-2025 | |
| Biogen, INC. | $40.26 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $29.03 | 2019 | |
| Lilly USA, LLC | $24.75 | 2019 | |
| Ge Healthcare | $20.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.00 | 2025 | Rexulti |
| Ipsen Biopharmaceuticals, INC | $19.32 | 2025 | Dysport |
| Avadel Cns Pharmaceuticals, LLC | $16.92 | 2024 | Lumryz |
| Philips North America LLC | $15.14 | 2020 | |
| Horizon Therapeutics Plc | $15.00 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $14.00 | 2024 | |
| Strongbridge US INC. | $12.84 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.52 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.38 | 2019 | |
| Acadia Pharmaceuticals INC | $12.04 | 2019 | |
| Amarin Pharma, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Danner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.